Bedside Snapshot
- Normal (Adult)
- <150 mg/dL (<1.7 mmol/L) fasting; <175 mg/dL (<2.0 mmol/L) non-fasting; 150–199 borderline; 200–499 high; 500–999 very high
- Critical Values
- ≥1000 mg/dL (≥11.3 mmol/L): typical pancreatitis-risk level; lab-specific reporting thresholds vary
- High Suggests
- Obesity, insulin resistance, diabetes
- Alcohol, high refined-carbohydrate intake
- Hypothyroidism, CKD, nephrotic syndrome
- Oral estrogen, pregnancy, familial hypertriglyceridemia
- Low Suggests
- Rarely clinically significant; malnutrition or malabsorption, and lipid-lowering drugs (fibrates, omega-3)
- Act Now If
- TG ≥1000 mg/dL with abdominal pain, vomiting or milky serum: treat as pancreatitis risk; serum lipase; treat pain and nausea per protocol; notify receiving team
- Watch Out For
- A lipemic sample can falsely lower sodium; a non-fasting result ≥440 mg/dL needs a fasting repeat
Reference & Critical Ranges
Lab-specific ranges: Every lab sets its own intervals, and they vary by analyzer and population. Use the range on your lab report. The values below are typical.
Reference ranges
| Population | Conventional | SI | Notes |
|---|---|---|---|
| Adult: normal | <150 mg/dL fasting; <175 mg/dL non-fasting | <1.7 mmol/L fasting; <2.0 mmol/L non-fasting | EAS/EFLM consensus cut-points |
| Adult: borderline high | 150–199 mg/dL | 1.7 to <2.3 mmol/L | Category as on most US lab reports |
| Adult: high | 200–499 mg/dL | 2.3 to <5.65 mmol/L | Treat by cardiovascular risk |
| Adult: very high | 500–999 mg/dL | 5.65 to <11.3 mmol/L | Pancreatitis risk rises |
| Child 0–9 years | <75 / 75–99 / ≥100 mg/dL | <0.85 / 0.85–1.12 / ≥1.13 mmol/L | Acceptable / borderline / high (NHLBI pediatric panel) |
| Adolescent 10–19 years | <90 / 90–129 / ≥130 mg/dL | <1.02 / 1.02–1.46 / ≥1.47 mmol/L | Acceptable / borderline / high (NHLBI pediatric panel) |
| Pregnancy | Physiologic rise in later trimesters | — | Interpret with obstetric context |
Severity & critical values
| Level | Conventional | SI | What it means |
|---|---|---|---|
| Normal | <150 mg/dL | <1.7 mmol/L | Lowest cardiovascular concern |
| Borderline high | 150–199 mg/dL | 1.7 to <2.3 mmol/L | Risk-based review and lifestyle measures |
| High | 200–499 mg/dL | 2.3 to <5.65 mmol/L | Treat by cardiovascular risk; look for secondary causes |
| Very high | 500–999 mg/dL | 5.65 to <11.3 mmol/L | Pancreatitis risk rises; urgent lowering plan |
| Critical | ≥1000 mg/dL | ≥11.3 mmol/L | Acute pancreatitis risk; urgent lipid-lowering plan; emergency evaluation if abdominal pain or vomiting (typical; lab-specific) |
Critical values: ≥1000 mg/dL (≥11.3 mmol/L) is the typical pancreatitis-risk level. Labs set their own reporting thresholds. Abdominal pain with a result this high? That patient needs immediate clinical assessment.
Conversion: mg/dL × 0.0113 = mmol/L
Friedewald LDL-C (valid only when TG <400 mg/dL)
LDL-C = total cholesterol − HDL-C − (TG ÷ 5)
Normal: there is no single number. The current guideline sets the LDL-C and non-HDL-C targets, based on the patient's risk category.
Non-HDL cholesterol
Non-HDL-C = total cholesterol − HDL-C
Normal: no single value applies. Use the target the current guideline sets. Non-HDL-C does not hinge on the Friedewald TG limit.
Causes of Abnormal Results
High (hypertriglyceridemia, TG ≥200 mg/dL)
| Mechanism | Common causes | Bedside clue |
|---|---|---|
| Overproduction by liver | Obesity, insulin resistance, diabetes, alcohol, high refined-carbohydrate intake, smoking, physical inactivity | Central obesity, metabolic syndrome features |
| Other conditions | Uncontrolled diabetes and diabetic ketoacidosis (a classic cause of severe HTG); lupus; monoclonal gammopathy; metabolic syndrome | Glucose and ketones; lipemic serum; check for pancreatitis symptoms |
| Reduced clearance | Hypothyroidism, CKD, nephrotic syndrome, liver disease | Check TSH, creatinine and urine protein |
| Genetic | Familial hypertriglyceridemia; familial combined hyperlipidemia; familial dysbetalipoproteinemia (type III); familial chylomicronemia (lipoprotein lipase or apoC-II deficiency) | Early onset, family history, recurrent pancreatitis, eruptive xanthomas |
| Drugs and hormones | Oral estrogen, glucocorticoids, non-selective beta-blockers, thiazide diuretics, atypical antipsychotics, isotretinoin, tamoxifen, protease inhibitors, bile acid sequestrants, cyclosporine, tacrolimus, sirolimus | Timeline: rise after starting the drug |
| Pregnancy | Physiologic rise in later trimesters; can unmask familial hypertriglyceridemia | Third trimester; prior lipid history |
Metabolic syndrome counts TG ≥150 mg/dL as a diagnostic criterion. Alcohol and refined carbohydrate? They drive the liver to make triglyceride, often more than dietary fat does. In diabetic ketoacidosis, lipemic serum can also falsely lower the measured sodium.
Pancreatitis at ≥1000 mg/dL: Triglycerides break down into free fatty acids, and those injure pancreatic tissue. Risk rises as the levels climb. Acute pancreatitis from very high triglycerides can be severe. It comes back if the levels are not brought down.
Low (not usually clinically significant)
Low triglycerides rarely matter clinically. The causes are malnutrition, malabsorption and hyperthyroidism. Fibrates and omega-3 fatty acids also lower triglycerides.
Interpretation & Bedside Approach
Step-by-step approach
- Is it real? Confirm fasting status and draw time. Non-fasting is fine for screening. A non-fasting result of 440 mg/dL or more needs a fasting repeat. Milky serum means very high triglycerides.
- How sick is the patient? At 1000 mg/dL or more, epigastric pain, vomiting or other signs of pancreatitis move the priority from lipid management to emergency care. Symptoms are what shift it.
- Acute or chronic? Compare with prior results. A transient rise follows a meal, alcohol, acute illness, steroids or estrogen. A persistent value points to a chronic cause.
- Calculate derived values. Use non-HDL-C, which is total cholesterol minus HDL-C. Calculate Friedewald LDL-C only when TG is below 400 mg/dL. Above that, use direct LDL-C.
- Classify with current criteria. Use the category on the lab report. Statin decisions follow the 2026 ACC/AHA dyslipidemia guideline by cardiovascular risk. That guideline supersedes the 2018 AHA/ACC cholesterol guideline. Severe hypertriglyceridemia follows the Endocrine Society 2012 guideline.
- Escalate or dispose. TG ≥1000 mg/dL with symptoms: pancreatitis pathway and emergency transfer. TG ≥500 mg/dL: urgent lipid plan and secondary-cause workup. Lower values get risk-based treatment and follow-up.
Pattern table
| Pattern | Suggests |
|---|---|
| TG ≥1000 mg/dL with abdominal pain, vomiting or lipemic serum | Pancreatitis risk; check lipase; emergency evaluation |
| High TG with low HDL, high glucose or central obesity | Metabolic syndrome or insulin resistance |
| High TG with elevated TSH | Hypothyroidism as a contributor; treat and recheck |
| Very high TG from childhood, recurrent pancreatitis or eruptive xanthomas | Familial chylomicronemia; specialist referral |
| TG rise after starting oral estrogen, a steroid or isotretinoin | Drug-related; review need and timing |
Look at the trend before you trust one number. A result drawn after a meal or in the middle of acute illness can overstate the chronic level.
Management Priorities
Emergency: Triglycerides ≥1000 mg/dL with suspected pancreatitis
- Treat the pancreatitis: Analgesia, antiemetics and fluids per protocol. Check serum lipase. The ACG 2024 guideline supports early oral feeding when the patient tolerates it.
- Lower triglycerides urgently: Stop alcohol and offending drugs such as oral estrogen. Put the patient on a very low-fat diet as the dietitian directs. Treat hyperglycemia and diabetic ketoacidosis. For patients at risk of pancreatitis, a fibrate is first-line to lower triglycerides (Endocrine Society 2012). Insulin infusion and plasma exchange depend on protocol and specialist input, and the evidence for them in this setting is limited.
- Prevent recurrence: Long-term lipid plan with a specialist; screen for familial causes.
- Monitor and repeat: Repeat triglycerides on follow-up labs; check glucose during any insulin infusion; notify the receiving team.
Treatment by triglyceride level
| Level (mg/dL) | Approach |
|---|---|
| 150–499 | Lifestyle first (weight, alcohol, refined carbohydrate and fructose reduction, aerobic exercise); correct secondary causes; statin by ASCVD risk (2026 ACC/AHA dyslipidemia guideline, which supersedes 2018). Icosapent ethyl (Vascepa) is a statin adjunct for TG 150 mg/dL or more with established cardiovascular disease, or diabetes plus two or more additional cardiovascular risk factors (brand label). |
| 500–999 | Urgent secondary-cause correction; very low-fat diet and alcohol avoidance; fibrate for patients at risk of pancreatitis (Endocrine Society 2012). |
| ≥1000 | Emergency pathway above when symptoms are present; otherwise an urgent lipid-lowering plan with specialist input. |
Endocrine Society 2012 calls 1000–1999 mg/dL severe hypertriglyceridemia, and 2000 mg/dL or more very severe. For very severe disease, the treatment goal is below 1000 mg/dL.
Medications
| Drug | Adult dose | Pediatric dose (max) | Onset / key notes |
|---|---|---|---|
| Insulin, IV (regular) | Protocol-based infusion with glucose monitoring; titrate to glucose; no fixed max | Not routinely used (consult) | High-alert Hypoglycemia risk; evidence in hypertriglyceridemic pancreatitis is limited; see insulin |
| Fenofibrate (oral) | 48–145 mg PO once daily; max 145 mg/day | Not established: consult | Lowers TG. Contraindicated in severe renal impairment (including dialysis), active liver disease and gallbladder disease. Warnings: pancreatitis, cholelithiasis, myopathy (higher with statins). The 48–145 mg dose shown is for Tricor-type tablets; the generic label checked lists 54 mg and 160 mg tablets, which are not interchangeable. |
| Icosapent ethyl (Vascepa) | 2 g PO twice daily with food; 4 g/day total | Not established: consult | Brand label (Vascepa): statin adjunct to reduce cardiovascular risk when TG is 150 mg/dL or more with established cardiovascular disease or diabetes plus two or more additional risk factors. Generic label checked: adjunct to diet for severe hypertriglyceridemia (TG ≥500 mg/dL). Warnings: atrial fibrillation or flutter; bleeding, higher with anticoagulants or antiplatelet drugs; fish allergy. |
| Omega-3 acid ethyl esters (Lovaza) | 4 g/day PO, adjunct to diet; 4 g/day max | Not established: consult | For TG ≥500 mg/dL; LDL-C may rise, so monitor LDL-C periodically during therapy; reduction of pancreatitis or cardiovascular events not established (per label) |
| Gemfibrozil (oral) | Label dose 1200 mg/day as 600 mg PO twice daily, 30 minutes before the morning and evening meals; 1200 mg/day | Not established: consult | Contraindicated with severe renal or hepatic dysfunction, gallbladder disease, and combination with simvastatin, repaglinide, dasabuvir or selexipag. Avoid rosuvastatin; if unavoidable, start 5 mg daily and do not exceed 10 mg daily. Warfarin: reduce the warfarin dose and monitor prothrombin time. Strong CYP2C8 and OATP1B1 inhibitor: dose reductions may be needed for their substrates. Other statins and colchicine: myopathy risk; check the current label and a pharmacist before combining with any other drug |
High-alert insulin: Get an independent double-check. Run it on an infusion pump with frequent glucose checks, under a written protocol.
Definitive care & disposition
- Admission: Severe hypertriglyceridemia with pancreatitis. Organ failure means ICU care.
- Specialist lipid referral: Persistent TG ≥500 mg/dL, suspected familial chylomicronemia, or recurrent pancreatitis.
- Dietitian referral: For patients at risk of pancreatitis. The aim is to cut dietary fat and simple-carbohydrate intake (Endocrine Society 2012).
- Follow-up: Repeat TG after treatment. Check TSH and glucose as part of the secondary-cause workup.
Doses are typical references. Doses vary by protocol; follow local protocols and medical direction.
Special Populations
| Population | What changes | Clinical implication |
|---|---|---|
| Neonates & infants | Severe hypertriglyceridemia is usually genetic when present | Specialist evaluation; reference intervals are not the adult ones |
| Children & adolescents | Lower age-specific cutoffs (see table); familial chylomicronemia can present in childhood | Use age-specific cutoffs; screen family history; pediatric drug dosing requires specialist input |
| Pregnancy | Physiologic rise in later trimesters; can unmask familial risk | Pancreatitis in pregnancy is an obstetric and maternal-fetal medicine emergency; manage with diet, glycemic control and specialist-directed therapy. Endocrine Society 2012: gemfibrozil may be considered in very severe cases from the second trimester. |
| Older adults | TG often rises with age and comorbidity | No separate threshold; interpret with diabetes, thyroid and renal status |
| CKD / dialysis | Impaired triglyceride clearance | Check triglycerides with renal workup; worsening renal function raises levels |
| Liver disease | Impaired lipoprotein metabolism | Interpret with liver panel; cirrhosis can change lipid patterns |
Interfering Factors & Pitfalls
Collection & handling
| Factor | Effect | Why | Avoid / fix |
|---|---|---|---|
| Non-fasting sample | ↑ TG | Chylomicrons from a recent meal | Record fasting time; a non-fasting result of 440 mg/dL or more needs a fasting repeat |
| Recent alcohol | ↑ TG | Alcohol increases hepatic triglyceride synthesis | Ask about intake in the previous 24 hours |
| Lipemic (milky) sample | False − sodium | Lipid displaces plasma water in indirect ion-selective assays | Repeat sodium by a method the lab confirms is not affected |
Medications & supplements
| Factor | Effect | Why | Avoid / fix |
|---|---|---|---|
| Propofol and IV lipid emulsions | ↑ TG | Exogenous fat in the infusion | In at-risk patients, monitor TG or serum turbidity during prolonged infusion; adjust propofol if fat is not being cleared (label section 5.10); reduce concurrent lipid (parenteral nutrition) calories |
| Glycerol-containing products | False + (some assays) | Glycerol is measured as triglyceride by some enzymatic assays that lack a glycerol blank | Ask the lab whether the assay corrects for glycerol; repeat on a method that does |
| Oral estrogen | ↑ TG | Increases hepatic VLDL production | Transdermal estrogen has less effect; avoid oral estrogen when TG is high |
Physiologic & biologic
- Acute illness, stress or pancreatitis: Values can shift. Read them against the trend and the clinical course.
- Lipemia: It can throw off other tests run on the same sample.
Assay & calculation
- Friedewald LDL-C at TG ≥400 mg/dL: Friedewald does not apply here. Use direct LDL-C or non-HDL-C.
Common misinterpretations
- At 1000 mg/dL or more, the value needs a prompt lipid-lowering plan. Abdominal pain or vomiting means emergency evaluation, even if the patient looks well.
- Non-fasting is fine for screening. It does not replace a fasting repeat when the value is high.
- A normal triglyceride level does not rule out other lipid abnormalities. Review the full panel.
Physiology & Test Basics
What it measures
This page covers blood triglycerides. They are measured apart from the cholesterol fractions on the lipid panel. Triglycerides are the main fat in blood and in storage. They are also the transport fat in chylomicrons and VLDL.
Physiology & regulation
- Dietary fat: The intestine packs it into chylomicrons. Lipoprotein lipase on the capillary walls clears it.
- Hepatic fat: The liver packs triglyceride into VLDL. Insulin promotes that. Insulin resistance pushes it higher.
- Clearance: ApoC-II switches on lipoprotein lipase, and lipoprotein lipase breaks down triglyceride in chylomicrons and VLDL. A deficiency of either one causes familial chylomicronemia.
- Alcohol and carbohydrate: Both push up hepatic triglyceride synthesis.
- Thyroid: Hypothyroidism dials down lipoprotein lipase activity. Clearance slows.
How it is measured
Serum or plasma from a standard lipid panel draw. The laboratory sets the tube type and the fasting instruction. Chemistry analyzers measure it enzymatically. Record fasting status and sample clarity. Lipemic serum can interfere with other assays.
Why it matters
At 1000 mg/dL or more, triglycerides hit a recognized pancreatitis threshold. At 500 mg/dL or more, they call for an urgent lipid plan. During prolonged propofol or lipid-containing nutrition, triglycerides can climb. Trend them.
Clinical Pearls
Triglycerides ≥1000 mg/dL = pancreatitis risk: Symptoms present? Treat it as urgent. Check lipase, stop alcohol and offending drugs, and start a specialist lipid plan.
Milky serum means very high triglycerides: Cloudy in the tube before it is spun? That points to very high TG. It also interferes with other results.
Non-fasting is acceptable for screening: A high non-fasting value, 440 mg/dL or more, needs a fasting repeat before diagnosis.
Friedewald LDL-C is not valid at TG ≥400 mg/dL: Reach for direct LDL-C or non-HDL-C as the treatment reference.
Check secondary causes first: Look at TSH, glucose, alcohol history, oral estrogen and recent medication changes. Those explain many high results.
ICU and transport nursing: During a prolonged propofol infusion, trend triglycerides or watch the serum for turbidity. Per the Diprivan label, adjust the propofol dose if fat is not being cleared. Reduce concurrently administered lipids.
EMS: There is no field triglyceride test. Epigastric pain and vomiting in a patient with known or suspected very high triglycerides means transport and a pancreatitis-aware handoff.
Oral estrogen raises triglycerides: Oral estrogen is the one to avoid when triglycerides run high. Transdermal estrogen has less effect on them.
Alcohol and carbohydrate first: Alcohol and refined carbohydrate both drive hepatic synthesis, so they raise triglycerides. Ask about both before you blame dietary fat for a high value.
References
- Berglund L, et al. Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2012;97(9):2969–2989. https://pmc.ncbi.nlm.nih.gov/articles/PMC3431581
- Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2026;153(17):e1154–e1276. Retires and replaces the 2018 AHA/ACC cholesterol guideline. https://doi.org/10.1161/CIR.0000000000001423
- Nordestgaard BG, et al. Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points. Joint consensus statement, European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. Eur Heart J. 2016;37:1944–1958. https://doi.org/10.1093/eurheartj/ehw152
- Tenner S, Vege SS, Sheth SG, et al. American College of Gastroenterology Guidelines: Management of Acute Pancreatitis. Am J Gastroenterol. 2024;119(3):419–437. https://doi.org/10.14309/ajg.0000000000002645
- Fenofibrate tablets, USP (generic) prescribing information. Revised 2022. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8e58c13a-8088-4fed-86cc-52530de5aa45
- Icosapent ethyl prescribing information: VASCEPA (Amarin Pharma Inc., revised 3/2026), https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9c1a2828-1583-4414-ab22-a60480e8e508; and generic icosapent ethyl capsules, DailyMed, accessed 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fd2b5373-1ddd-46c0-a579-d5a4f289d79f
- Diprivan (propofol) injectable emulsion prescribing information. Fresenius Kabi USA. Revised 1/2025; section 5.10. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e3105799-a4b6-f3f4-e6e2-b2b29bbdb538
- LOPID (gemfibrozil) tablets prescribing information. Parke-Davis, Pfizer. Revised August 2023 (DailyMed page updated May 2026). DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c48855b7-215e-453b-b3b1-a0f9dee7221f
Medical Disclaimer
- For Educational Purposes Only: This content is intended for educational reference and should not be used for clinical decision-making.
- Not a Substitute for Professional Judgment: Always consult your local protocols, institutional guidelines, and supervising physicians.
- Verify Before Acting: Users are responsible for verifying information through authoritative sources before any clinical application.
AI Assistance Notice
AI was used to assist in organizing, paraphrasing, and formatting this information.